Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Accounts Payables: 2017-2024

Historic Accounts Payables for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $23.7 million.

  • Protagonist Therapeutics' Accounts Payables rose 10.27% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 10.27%. This contributed to the annual value of $23.7 million for FY2024, which is 22.39% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Accounts Payables of $23.7 million as of FY2024, which was up 22.39% from $19.4 million recorded in FY2023.
  • Protagonist Therapeutics' Accounts Payables' 5-year high stood at $37.7 million during FY2021, with a 5-year trough of $18.5 million in FY2020.
  • In the last 3 years, Protagonist Therapeutics' Accounts Payables had a median value of $23.7 million in 2024 and averaged $22.7 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Accounts Payables spiked by 103.89% in 2021, and later crashed by 33.83% in 2022.
  • Protagonist Therapeutics' Accounts Payables (Yearly) stood at $18.5 million in 2020, then soared by 103.89% to $37.7 million in 2021, then plummeted by 33.83% to $25.0 million in 2022, then dropped by 22.43% to $19.4 million in 2023, then grew by 22.39% to $23.7 million in 2024.